Besides its well-known effect on calcium homeostasis, the active form of vitamin D 1a,25-dihydroxyvitamin D 3 (1,25(OH) 2 D 3 ) regulates the growth and differentiation of cancer cells and inhibits, alone or in combination with cyclosporin A, autoimmune disease and graft rejection in several experimental transplantation models. The immunosuppressive effect of 1,25(OH) 2 D 3 is based on the modulation of immune cell differentiation and function. 1 1,25(OH) 2 D 3 positively influences the differentiation of monocytes into macrophages, whereas the function of lymphocytes and the differentiation of dendritic cells (DC) are suppressed. 2 Vitamin D receptor (VDR) deficient mice show an unresponsiveness to 1,25(OH) 2 D 3 and have increased numbers of DC in lymph nodes, suggesting a physiologically relevant inhibition of DC differentiation by 1,25(OH) 2 D 3 . 3 As inactivation of host DC has been proposed to prevent graft-versus-host disease (GvHD) in allogeneic bone marrow transplantation (BMT), the inhibition of DC differentiation by 1,25(OH) 2 D 3 could prevent T-cell activation in the course of alloreactions. Accordingly, it has been shown that vitamin D analogs prevent acute GvHD in rat BMT and that the VDR gene polymorphism associates with GvHD and survival. 4, 5 Up to now, no data are available on the endogenous serum levels of vitamin D metabolites during the course of BMT. In this study we measured 25-hydroxyvitamin D 3 (25(OH)D 3 ) and 1,25(OH) 2 D 3 in consecutive serum samples of 48 patients before and after allogeneic BMT.
Patients received standard conditioning consisting of fractionated total body irradiation (8-12 Gy) followed by cyclophosphamide 2 Â 60 mg/kg or reduced-intensity conditioning including fludarabin/BCNU and melphalan. 6 Cyclosporin and a short course of methotrexate or mycophenolate mofetil were used for prevention of GvHD. Prednisolone at a dose of 2 mg/kg was used for first-line treatment of GvHD, monoclonal antibodies blocking IL-2 the receptor (ZenapaxR) or TNF-antagonists (etanercept) were given to patients with resistant or relapsing acute GvHD. Chronic GvHD was treated with CsA and prednisolone or extracorporal photopheresis. Besides creatinine, CsA levels and other routine parameters, analyses of 25(OH)D 3 and 1,25(OH) 2 D 3 were performed. Informed consent for collection of serum samples had been obtained from all patients.
We observed a marked decline in the serum levels of both vitamin D 3 metabolites in the course of allogeneic BMT. serum levels were first found during aplasia and thereafter during maximum GvHD. Synthesis of 1,25(OH) 2 D 3 from its precursor 25(OH)D 3 normally occurs in the kidney; however, several reports describe extrarenal production of 1,25(OH) 2 D 3 . 8, 9 Therefore, we hypothesize that the drop in 1,25(OH) 2 D 3 levels during aplasia may in part be due to the drop in leukocyte, especially monocyte counts, which recovers after engraftment in the absence of GvHD. The persisting or even worsening decline of vitamin D 3 metabolites in patients with severe GvHD was unexpected and cannot be explained by secondary suppression of monocyte counts.
The results on low vitamin D 3 metabolite levels are not surprising, taking into account that osteoporosis and even osteonecrosis are potential complications not only in solid organ transplantation but also in recipients of BMT. Bone mineral density of BMT patients is decreased during the first years after BMT. This is often correlated with CsA and glucocorticoid levels but up to now two studies also found a correlation with low 25(OH) 2 D 3 levels. To prevent osteoporosis patients often receive vitamin D 3 , the precursor of 25(OH)D 3 , however, in the study by Schulte et al 10 patients had low 25(OH)D 3 serum levels despite the fact that they were supplemented with vitamin D 3 . As our data show that deficiency is not only found for 25(OH)D 3 but also for 1,25(OH) 2 
